A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized studyAgnieszka Wierzbowska, Gail J. Roboz, Karol Wójcik et al.|Blood|2025Cited by 1
The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 StudyAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2021Cited by 0
Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 StudyAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2022Cited by 0
A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)Agnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2020Cited by 0
A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline ResultsAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2024Cited by 0